HC Wainwright Forecasts Sight Sciences Q1 Earnings

Sight Sciences, Inc. (NASDAQ:SGHT) – Investment analysts at HC Wainwright issued their Q1 2027 EPS estimates for Sight Sciences in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst Y. Chen anticipates that the company will earn ($0.09) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Sight Sciences’ current full-year earnings is ($0.48) per share.

Sight Sciences (NASDAQ:SGHT) last posted its earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). Sight Sciences had a negative net margin of 32.13% and a negative return on equity of 42.41%. The business had revenue of $24.92 million for the quarter, compared to analyst estimates of $23.55 million.

A number of other equities analysts also recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up from $9.00) on shares of Sight Sciences in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Wednesday. Wall Street Zen upgraded Sight Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. UBS Group upped their target price on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Citigroup increased their target price on Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, October 5th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.62.

Sight Sciences Price Performance

Shares of Sight Sciences stock opened at $9.76 on Friday. The company has a quick ratio of 4.67, a current ratio of 4.95 and a debt-to-equity ratio of 0.58. Sight Sciences has a twelve month low of $3.38 and a twelve month high of $10.31. The business has a 50-day moving average price of $8.68 and a 200 day moving average price of $6.07. The firm has a market cap of $537.66 million, a PE ratio of -18.77 and a beta of 2.44.

Institutional Investors Weigh In On Sight Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd grew its holdings in shares of Sight Sciences by 20.7% during the third quarter. R Squared Ltd now owns 19,759 shares of the company’s stock worth $185,000 after buying an additional 3,388 shares in the last quarter. Hsbc Holdings PLC raised its position in shares of Sight Sciences by 21.6% in the second quarter. Hsbc Holdings PLC now owns 46,707 shares of the company’s stock valued at $255,000 after buying an additional 8,297 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Sight Sciences in the second quarter valued at about $520,000. Canada Pension Plan Investment Board acquired a new stake in shares of Sight Sciences in the second quarter valued at about $299,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Sight Sciences in the second quarter worth about $60,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Insider Transactions at Sight Sciences

In other news, CEO Paul Badawi sold 29,653 shares of Sight Sciences stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $268,359.65. Following the sale, the chief executive officer directly owned 6,092,819 shares of the company’s stock, valued at $55,140,011.95. The trade was a 0.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO James Rodberg sold 7,208 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $8.85, for a total value of $63,790.80. Following the sale, the chief financial officer owned 216,829 shares of the company’s stock, valued at $1,918,936.65. The trade was a 3.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 47,646 shares of company stock worth $429,157 over the last three months. 30.40% of the stock is owned by insiders.

Key Headlines Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Higher 2026 outlook: Sight Sciences raised its full-year revenue guidance to $92–$93 million and indicated a higher 2026 revenue target for its iDose product. The improved outlook may support expectations for continued growth. Article: Sight Sciences signals 2026 revenue outlook
• Positive Sentiment: CMS reimbursement development: CMS established a direct practice-expense supply code for TearCare SmartLids, a single-use component of the TearCare system. This could help clarify reimbursement and support adoption. Article: CMS establishes a TearCare SmartLids supply code
• Positive Sentiment: Revenue beat and analyst support: Third-quarter revenue was $24.92 million, above analysts’ $23.55 million estimate. Piper Sandler reaffirmed its Overweight rating and raised its price target to $12 from $9, signaling confidence in further upside. Analyst rating information
• Neutral Sentiment: Losses persist, but met expectations: SGHT reported a third-quarter loss of $0.12 per share, in line with consensus and narrower than the $0.16 loss a year earlier. The company remains unprofitable, which may temper the positive growth news. Article: Sight Sciences reports Q3 loss and revenue beat

About Sight Sciences

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.